logo
Share SHARE
FONT-SIZE Plus   Neg

Threshold Issues Updated Results From Phase 2 Study Of TH-302 - Quick Facts

Threshold Pharmaceuticals, Inc. (THLD) announced updated results from a Phase 2 study of TH-302, the company's investigational hypoxia-targeted drug, in patients with soft tissue sarcoma, including additional results from patients who were administered TH-302 as single agent maintenance therapy following induction with TH-302 in combination with doxorubicin.

In the single-arm Phase 2 component of the study, previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcomas were treated with TH-302 and doxorubicin for a maximum of six cycles. After six cycles, patients with stable disease, partial or complete responses, and with acceptable toxicity, were eligible to receive TH-302 maintenance therapy. Response was assessed using RECIST criteria.

In overall study population, results for the 91 patients in the Phase 2 component of the study include median progression free survival of 6.7 months, median overall survival of 21.5 months, one-year survival of 73% and two-year survival of 44% and overall best response of 36%.

The company also reported results for TH-302 single agent maintenance therapy population. The median number of treatment cycles with TH-302 was 4.0. Median PFS was 3.7 months. Median overall survival was 18 months. Overall best response was 54%.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Cisco Systems Inc. (CSCO), the world's largest computer networking gear maker, is accelerating its ability to deliver on growth opportunities, aggressively driving its cloud business, and delivering continued strength in its deferred product revenue, as we sell more of its portfolio in software and cloud models. In fiscal 2016, the company sees a 25% increase in major new product introductions. Sanofi (SNYNF, SNY) reported that its fourth-quarter net income attributable to equity holders decreased to 334 million euros from 1.34 billion euros, last year. Earnings per share was 0.26 euros compared to 1.02 euros. Earnings per share excluding the held for exchange Animal Health Business was 0.41... Tour operator TUI Group reported narrower EBITA loss in its first quarter with increased turnover, driven by strong performances in Northern Region and Cruises. Further, the company said its current trading for Winter 2015/2016 and Summer 2016 remains in line with its expectations. Looking ahead, TUI reiterated its outlook to deliver underlying EBITA growth of at least 10 percent in fiscal 2016.
comments powered by Disqus
RELATED NEWS
Trade THLD now with 
Follow RTT